EXAMINATION REPORT

OF

HIGHMARK BCBSD INC.

AS OF

DECEMBER 31, 2021

TRINIDAD NAVARRO COMMISSIONER



STATE OF DELAWARE DEPARTMENT OF INSURANCE

REPORT ON EXAMINATION

OF

HIGHMARK BCBSD, INC.

AS OF

DECEMBER 31, 2021

The above-captioned report was completed by examiners of the Delaware Department of Insurance.

Consideration has been duly given to the comments, conclusions and recommendations of the examiners regarding the status of the company as reflected in the report.

This report is hereby accepted, adopted and filed as an official record of this Department.

Janano

Trinidad Navarro Insurance Commissioner

Dated this <u>7th</u> day of <u>June</u>, 2023

◆INSURANCE.DELAWARE.GOV◆ 1351 W. NORTH ST., SUITE 101, DOVER, DELAWARE 19904 (302) 674-7300 DOVER◆ (302) 259-7554 GEORGETOWN◆ (302) 577-5280 WILMINGTON

TABLE OF CONTENTS

SCOPE OF EXAMINATION1
SUMMARY OF SIGNIFICANT FINDINGS
HISTORY
CAPITALIZATION
DIVIDENDS
SURPLUS NOTE 4
MANAGEMENT AND CONTROL
DIRECTORS
Committees
Officers7
CORPORATE RECORDS
INSURANCE HOLDING COMPANY SYSTEM
AGREEMENTS WITH AFFILIATES
TERRITORY AND PLAN OF OPERATION11
Territory
PLAN OF OPERATION
REINSURANCE
Assumed
CEDED
REINSURANCE CONTRACT REVIEW14
FINANCIAL STATEMENTS 15
ANALYSIS OF CHANGES IN FINANCIAL STATEMENTS RESULTING FROM THE
EXAMINATION
COMMENTS ON FINANCIAL STATEMENT ITEMS 20
SUBSEQUENT EVENTS
SUMMARY OF RECOMMENDATIONS

May 31, 2023

Honorable Trinidad Navarro Commissioner Delaware Department of Insurance 1351 W. North St., Suite 101 Dover, Delaware 19904

Commissioner:

In compliance with instructions and pursuant to statutory provisions contained in Examination Certification No. 22.013, dated January 11, 2022, an examination has been made of the affairs, financial condition and management of

HIGHMARK BCBSD INC.

hereinafter referred to as the Company or BCBSD. The Company was incorporated under the laws of the State of Delaware as a non-stock company with its registered and home office located at 800 Delaware Avenue, Wilmington, Delaware 19801. The Company's administrative office is located at 120 Fifth Avenue, Pittsburgh, Pennsylvania 15222.

SCOPE OF EXAMINATION

We have performed our multi-state examination of BCBSD. The last examination was conducted as of December 31, 2019, by the Delaware Department of Insurance (Department). This examination covers the two-year period from January 1, 2020 through December 31, 2021. Our examination was performed as part of the coordinated multi-state examination of the Highmark

Health Group (HH). The lead state for the coordinated examination is the Pennsylvania Insurance Department.

We conducted our examination in accordance with the *National Association of Insurance Commissioners* (NAIC) *Financial Condition Examiners Handbook* (Handbook) and generally accepted statutory insurance examination standards consistent with the Insurance Code and Regulations of the State of Delaware The Handbook requires that we plan and perform the examination to evaluate the financial condition, assess corporate governance, identify current and prospective risks of the company and evaluate system controls and procedures used to mitigate those risks. An examination also includes identifying and evaluating significant risks that could cause an insurer's surplus to be materially misstated both currently and prospectively.

All accounts and activities of the Company were considered in accordance with the riskfocused examination process. This may include assessing significant estimates made by management and evaluating management's compliance with Statutory Accounting Principles. The examination does not attest to the fair presentation of the financial statements included herein. If, during the course of the examination an adjustment is identified, the impact of such adjustment will be documented separately following the Company's financial statements.

This examination report includes significant findings of fact, as mentioned in 18 *Del. C.* § 321, and general information about the insurer and its financial condition. There may be other items identified during the examination that, due to their nature (e.g., subjective conclusions, proprietary information, etc.), are not included within the examination report but separately communicated to other regulators and/or the Company.

During the course of this examination, consideration was given to work performed by the Company's external accounting firm, PricewaterhouseCoopers LLP (PwC). Certain auditor work

papers of the 2021 audit of the Company have been incorporated into the work papers of the examiners and have been utilized in determining the scope, areas of emphasis in conducting the examination and in the area of risk mitigation and substantive testing.

SUMMARY OF SIGNIFICANT FINDINGS

There were no significant findings or material changes in financial statements as a result of this examination.

COMPANY HISTORY

The Company was originally incorporated by the filing of a Certificate of Incorporation with the Secretary of State on August 16, 1935, as a private non-profit, non-stock corporation. The Company operates as a health service corporation in the State of Delaware and is a licensee of the Blue Cross and Blue Shield Association. The Company continues to underwrite various indemnity and managed care health insurance products, as well as Medicare supplemental, dental and vision products and also provides administrative services contracts to self-funded plans.

On December 30, 2011, the Delaware Commissioner approved an affiliation between Highmark Inc. (Highmark) and the Company imposing forty-nine (49) conditions on the affiliation that, among other things, were intended to preserve the Company's surplus and make it possible for the Company to disaffiliate, if necessary. Effective January 1, 2012, Highmark became the sole member of the Company, giving it the authority to elect the Company's Board of Directors (Board). The Company is a separate legal entity and is not liable for Highmark's obligations. In accordance with the Amended and Restated Certificate of Incorporation, in the event the Company dissolves, the Directors shall cause any remaining assets of the Company to be distributed to a foundation created pursuant to 29 *Del. C.* § 2533, or to a federally tax-

exempt organization. The Directors have discretion as to which qualified organization or organizations receive the distribution.

On April 26, 2013 the Delaware Commissioner approved the indirect control of the Company by the ultimate parent entity, later named Highmark Health (HH). On April 29, 2013, lead State Pennsylvania's Insurance Department approved the affiliation of Highmark/West Penn Allegheny Health System. Pursuant to these two orders, HH became the sole member of Highmark and the ultimate controlling entity within the holding company system.

Capitalization

In accordance with Article III, Section 3.1 of its amended and restated bylaws, the Company is a membership corporation, operating as a not-for-profit organization, with no authority to issue capital stock.

Dividends

The Company's organizational structure does not allow for dividends to be paid.

Surplus Note

On December 31, 2021, the Company held an unrated \$10,000,000 surplus note from Highmark BCBSD Health Options Inc. (HHO) that was originally acquired on November 21, 2014. The surplus note has a stated maturity date of December 31, 2025, and interest is accrued at a variable rate per annum equal to the most recently issued one year U.S. Treasury Bill plus 650 basis points. Because the surplus note is not rated by the NAIC's Investment Analysis Office, in accordance with SSAP No. 41, a statement factor was applied which reduced the admitted value of the surplus note to \$0 on December 31, 2021.

MANAGEMENT AND CONTROL

Directors

Pursuant to Article V, Section 5.2(a) of the Company's amended and restated bylaws, the number of Directors that constitutes a full Board shall be nine (9), consisting of four (4) Class 'A' Directors, four (4) Class 'B' Directors and the President of the Company in office. The number of Directors may be changed from time to time, in accordance with Article 13 of the amended and restated Certificate of Incorporation.

Each Class 'B' Director shall be elected annually by the sole member. Each Class 'A' Director shall hold office for three (3) years and then is subject to nomination by the Nominating Committee. The majority of the Board shall consist of: 1) persons not employed by the Company or any of its affiliates and 2) persons who are residents of the State of Delaware and have been so for at least five (5) years. Directors serving on the Company's Board as of December 31, 2021, were as follows:

<u>Name and Residence</u>	Principal Occupation
Nicholas Anthony Moriello	President
Lincoln University, Pennsylvania	Highmark BCBSD INC.
William Harvey Willis, Jr. (Class A) (CH) Smyrna, Delaware	Automobile Dealer
William Dennis Cronin (Class B)	Senior Vice President, Treasury
Oakdale, Pennsylvania	Highmark Health
Timothy John Constantine (Class B) Wilmington, Delaware	Executive Vice President, Commercial Markets Highmark Inc.
Michael George Warfel (Class B)	Vice President, Government Affairs
Camp Hill, Pennsylvania	Highmark Inc.
Randeep Singh Kahlon, M.D. (Class A)	Physician
Hockessin, Delaware	First State Orthopaedics
Gregory Brian Williams, Esquire (Class A)	Attorney
New Castle, Delaware	Fox Rothchild LLP, Citizens Bank Center
Anthony Richard Heffron (Class B) Hockessin, Delaware	Retired
Rita Maria Landgraf (Class A)	Adminstrator and Faculty
Wilmington, Delaware	University of Delaware - College of Health Sciences

Committees

Pursuant to Article V, Section 5.11 of the Company's amended and restated bylaws, the Board shall have two (2) standing committees: 1) Audit and Compliance Committee and 2) Nominating Committee. The Company may also have other ad hoc committees designated by resolution and passed by a majority of the Board in office. As of December 31, 2021, the following directors were members of the Audit and Compliance Committee:

Name	Principal Occupation
Randeep Singh Kahlon, M.D. (CH)	Physician, First State Orthopedics
Rita Marie Landgraf	Administrator and Faculty, University of Delaware
Anthony Richard Heffron	Retired
William Harvey Willis, Jr.	Automobile Dealer
Gregory Brian Williams, Esquire	Attorney, Fox Rothchild LLP, Citizens Bank Center

As of December 31, 2021, the following directors were members of the Nominating

Committee:

Name	Principal Occupation
Gregory Brian Williams, Esquire (CH)	Attorney, Fox Rothchild LLP, Citizens Bank Center
Randeep Singh Kahlon, M.D.	Physician, First State Orthopedics
Rita Marie Landgraf	Administrator and Faculty, University of Delaware
William Harvey Willis, Jr.	Automobile Dealer

Officers

Officers were elected in accordance with the bylaws during the period under examination. The bylaws require election of a President, Secretary and Treasurer. Any number of offices may be held by the same person except the offices of President and Secretary. The principal officers serving as of December 31, 2021, were as follows:

Name	Title
Nicholas Anthony Moriello	President
Edward August Bittner, Jr.	Secretary
Donald Hays Dabkowski	Treasurer

The Company maintains a formal written Code of Conduct, which sets out the ethical guidelines to which all directors, officers and employees are expected to adhere to on a consistent basis when conducting business at and on behalf of the Company. Incorporated into the Code of Conduct is a conflict-of-interest policy. All directors, officers and employees are required to

complete a Conflict-of-Interest Disclosure statement upon appointment or hire and on an annual basis thereafter, and throughout the year as changes in circumstances arise that may either give rise to a potential conflict of interest or change or eliminate a potential conflict previously disclosed.

Corporate Records

The recorded Board and Committee minutes were reviewed for the examination period. The Board minutes adequately documented the Board's meetings and approval of Company transactions and events including approval of investment transactions. In addition, review of the Company's files indicated that in general, written correspondence was submitted to the Department with regards to the changes in officers and directors during the period under examination.

Receipt by the Board of the Report on Examination as of December 31, 2019 was noted in the minutes of the Audit Committee on March 5, 2021.

Insurance Holding Company System

The Company is a member of an insurance holding company system as defined under 18 *Del. C.* § 5001 (7) of the Delaware Insurance Code. The ultimate controlling entity within the holding company system is HH. The Company's Holding Company Registration Statements were timely filed with the Department for the years under examination.

An abbreviated presentation of the holding company system as of December 31, 2021, is as follows:

Company	Domicile	<u>% own</u>
Highmark Health	Pennsylvania	
Highmark Inc. ⁽¹⁾	Pennsylvania	100%
Highmark BCBSD INC.	Delaware	100%
Highmark BCBSD Health Options Inc. ⁽²⁾	Delaware	100%

1. Highmark Inc. does business as Highmark Blue Cross Blue Shield and Highmark Blue Shield.

2. Highmark BCBSD Health Options Inc. is a Delaware non-profit company; the Company is the sole member.

Agreements with Affiliates

With the affiliation of the Company within the Highmark Group effective December 30, 2011, the Company entered into certain intercompany agreements. The Company's significant intercompany agreements in effect as of December 31, 2021, include:

Amended and Restated Administrative Services Agreement with Highmark Inc.

Effective January 1, 2012, the Company entered into an Administrative Services Agreement (ASA) with Highmark in connection with the Affiliation approval. The agreement establishes a plan of systems conversion and integration priorities, performance standards, budgets and timelines to be developed after the affiliation conversion. Highmark's charge to the Company for services provided under the agreement is an amount equal to the Company's fair and reasonable allocable share of the total actual cost without provision for profit. Such costs shall include, without limitation, employee salaries, employee benefits and other direct and indirect administrative costs, including reasonable charges for corporate overhead.

Effective November 13, 2013, the ASA with Highmark was amended to add a Service Level Amendment for the purpose of defining, managing and measuring performance levels of support which will be provided to the Company.

Administrative Services and Network Access Agreement with United Concordia

Effective May 29, 2013, and as subsequently amended on January 1, 2015, July 1, 2018 and April 1, 2020, the Company entered into an Administrative Services and Network Access

Agreement with United Concordia Companies, Inc. (United Concordia). The Company engaged United Concordia to provide certain services to administer and support services for the Company's Blue Cross Blue Shield-branded dental business. This Agreement applies to administration of dental products that are branded and written by the Company.

Administrative Services Agreement with Highmark Inc.

Effective July 9, 2014, the Company entered into an ASA with Highmark. Under the agreement, the Company provides certain administrative and corporate services and makes available certain facilities and equipment to Highmark for its business operations.

Investment Management Agreement with Highmark Health

Effective January 11, 2018, the Company entered into an Investment Management Agreement with HH. Under the agreement, HH performs investment management and investment advisor services. As the Company's investment manager, HH will act in conformity with the Company's Investment Policy, together with such amendments as provided to HH from time to time at Company's discretion. HH agreed that all funds and invested assets of Company are the exclusive property of the Company, held for the benefit of the Company and are subject to the control of the Company.

Administrative Services Agreement with Highmark and HHO

Effective November 1, 2019, the Company entered into an Administrative Services Agreement with Highmark and HHO, pursuant to which Highmark and the Company provide administrative and corporate services as well as certain facilities and equipment to HHO necessary for HHO to conduct its Medicaid business operations in Delaware.

TERRITORY AND PLAN OF OPERATION

Territory

The Company is licensed to solicit business as a Health Service Corporation in the State of Delaware only, and as of December 31, 2021, had approximately 106,935 members total for all lines of business.

Plan of Operation

The Company writes primarily comprehensive (medical and hospital) business and underwrites various indemnity and managed care health insurance products, as well as Medicare supplemental, dental and vision products. Most of the Company's business (approximately 51.4%) falls under the Federal ACA, and a significant portion of its business (approximately 48.6%) is not underwritten, meaning there is no insurance risk to the Company. For large, selfinsured accounts, the Company processes claims payments and receives reimbursement for claims and expenses from the account.

The Company also offers administrative services only (ASO) to groups and accounts throughout the State of Delaware. The administrative services provided include management of benefits, adjudication and payment of claims, response to inquiries from covered individuals and health care providers and providing Plan Sponsors with information enabling them to manage their health benefit programs. The Company's ASO business serviced approximately 233,296 members as of year-end 2021.

The Company's core health insurance products are categorized into two (2) major segments, Group and Individual, as follows:

- 1. Group Business
 - <u>Traditional</u>
 - Comprehensive Major Medical

<u>Senior</u>

• Medigap

Managed Care

- Exclusive Provider Organization, plan (EPO)
- Federal Employee Program (FEP)
- Preferred Provider Organization (PPO)
- Health Management Organization (HMO)⁽¹⁾
- 1. Per the Company there was a very small population in the HMO product during the examination.
 - 2. Individual Business

<u>Individual</u>

- Exclusive Provider Organization, plan (EPO)
- Preferred Provider Organization (PPO)

<u>Senior</u>

- Medigap Blue
- Medical Advantage Supplement product

The Company's 2021 direct premiums written by lines of business are reflected below:

Line of Business	Direct Premiums <u>Written</u>	Percent of <u>Premiums</u>
Individual Business	\$ 235,641,736	31.11%
Group Business ⁽¹⁾	311,778,431	<u>41.16%</u>
Total Comprehensive (Medical and Hospital)	\$ 547,420,167	72.28%
Medicare Supplement	22,035,856	2.91%
Dental Only	5,789,926	0.77%
Vision Only	1,225,362	0.16%
FEP ⁽²⁾	180,722,395	23.87%
Other Health	151,078	0.02%
Total Premiums	<u>\$ 757,344,784</u>	<u>100.00%</u>

^{1.} In 2021, approximately 50.26% or \$156,689,555 of the Group business was "ACA Small Group" business. The remaining 49.74% of the Company's "Group" business was non-ACA business in 2021.

2. The FEP Business is non-underwritten business; however, the NAIC Annual Statement has certain reporting requirements with regards to FEP business on certain schedules within the Annual Statement. As a result,

the Company must include the FEP business on the statutory balance sheet so that the balance sheet will tie to the supporting schedules of the Annual Statement.

REINSURANCE

For 2021, the Company reported the following distribution of net premiums written:

Direct	\$ 757,344,784
Reinsurance assumed (from affiliates)	-
Reinsurance assumed (from non-affiliates)	
Total direct and assumed	\$ 757,344,784
Reinsurance ceded (to affiliates)	-
Reinsurance ceded (to non-affiliates)	6,494,229
Net premium written	\$ 750,850,555

The Company had the following reinsurance program in effect as of December 31, 2021:

Assumed

The Company did not assume any business as of December 31, 2021 and does not have any assumed reinsurance contract in place.

Ceded

Effective January 1, 2019, the Company entered into a two-year excess of loss reinsurance contract with Renaissance Reinsurance U.S. Inc. to reinsure losses in excess of \$5,000,000 per covered person, per contract year on certain fully insured products of the Company. The contract permits either party to terminate, for cause, by giving no less than 30 days prior written notice for breach of the terms and conditions of the contract. This contract was not renewed upon expiration on January 1, 2021.

Effective July 19, 1994, amended May 2, 1995, the Company entered into an agreement with MedAmerica Insurance Company of New York (MANY), for one-hundred percent coverage of risk to reinsure the Company's long-term care (LTC) insurance. The Company's agreement

with MANY permits either party the right to terminate the agreement with 180 days' notice for new and renewal policies.

Effective September 1, 2020, the Company executed a reinsurance commutation agreement and mutual release with MANY. As of December 31, 2021, one-hundred percent of the LTC business ceded under the agreement with MANY had been commuted and settled.

In 2020, the State of Delaware, Delaware Health and Social Services (DHSS) implemented a state-run reinsurance program that reimburses individual plans that meet certain minimum criteria, as set forth in the *1332 State Innovation Waiver Application*. The fund is financed through an assessment on the individual, small and large group market premium amounts for all health insurance carriers operating in those markets in Delaware. The assessment will take place annually and may vary depending on the Federal government's actions on the annual fee under Section 9010 of the CARES Act.

There were no reinsurance credits taken in 2021.

Reinsurance Contract Review

A review was performed of reinsurance contracts put into place during the examination period for compliance with 18 *Del. Admin. Code* § 1000 "Reinsurance" ⁽¹⁾ and NAIC Guidelines and Statutory Accounting Principles (SSAP). No exceptions were noted.

^{1.} By its terms, 18 *Del. Admin. Code* § 1002 ("Life and Health Reinsurance Agreements") applies to "all domestic life and accident and health insurers and to all other licensed life and accident and health insurers which are not subject to a substantially similar regulation in their domiciliary state" without reference to health service corporations.

FINANCIAL STATEMENTS

The following financial statements, as reported and filed by the Company with the

Department, are reflected in the following:

General Account:

- Statement of Assets and Liabilities as of December 31, 2021
- Statement of Income for the Year ended December 31, 2021
- Reconciliation of Capital and Surplus for the Period from the Prior Examination as of December 31, 2019 to December 31, 2021

Statement of Assets and Liabilities As of December 31, 2021

		Assets	N	Assets Jonadmitted	1	Net Admitted Assets	Notes
Bonds	\$	420,012,981	\$	-	\$	420,012,981	
Common stocks	Ψ	137,278,895	Ψ	-	Ψ	137,278,895	
Cash, cash equivalents, short-term investments		36,943,600		-		36,943,600	
Other invested assets		13,573,298		10,000,000		3,573,298	
Receivables for securities		34,756		-		34,756	
Securities lending reinvested collateral assets		1,227,919		-		1,227,919	
Subtotals, cash and invested assets	\$	609,071,449	\$	10,000,000	\$	599,071,449	
Investment income due and accrued		2,672,960		-		2,672,960	
Premiums and considerations:							
Uncollected premiums and agents' balances							
in the course of collection		17,810,215		217,782		17,592,433	
Accrued retrospective premiums and contracts subject							
to redetermination		1,104,091		382,203		721,888	
Amounts recoverable from reinsurers		46,541,643		-		46,541,643	
Amounts receivable relating to uninsured plans		25,610,589		1,612,942		23,997,647	
Net deferred tax asset		16,897,839		6,820,305		10,077,534	
Electronic data processing equipment and software		222,277		102,799		119,478	
Furniture and equipment		33,958		33,958		-	
Receivables from parent, subsidiaries and affiliates		7,802,959		-		7,802,959	
Health care and other amounts receivable		27,849,680		3,335,889		24,513,791	
Aggregate write-ins for other than invested assets		1,170,529		1,170,529		_	
Total	\$	756,788,189	\$	23,676,407	\$	733,111,782	

		Notes
Claims unpaid	\$ 68,660,820	1
Accrued medical incentive pool and bonus amounts	2,106,227	
Unpaid claims adjustment expenses	1,984,768	
Aggregate health policy reserves, including the liability for		
medical loss ratio rebate per the Public Health Service Act	8,019,951	
Aggregate health claim reserves	2,025,608	
Premiums received in advance	14,018,895	
General expenses due or accrued	94,747,308	
Current federal and foreign income tax payable and interest thereon	497,632	
Remittances and items not allocated	847,689	
Amounts due to parent, subsidiaries and affiliates	46,764,556	
Payable for securities	169,475	
Payable for securities lending	1,227,919	
Liability for amounts held under uninsured plans	4,904,137	
Aggregate write-ins for other liabilities	24,585,543	_
Total liabilities	\$ 270,560,528	-
Unassigned funds (surplus)	462,551,254	-
Total Capital and Surplus	\$ 462,551,254	-
Total liabilities, capital and surplus	\$ 733,111,782	-

Statement of Income For the Year Ended December 31, 2021

Member months	1,248,436
Net premium income	\$ 750,850,555
Change in unearned premium reserves and reserve for rate credits	7,186,998
Total revenue	\$ 758,037,553
Hospital and Medical:	
Hospital / medical benefits	\$ 526,899,361
Prescription drugs	142,750,159
Aggregate write-ins for other hospital and medical	5,188,698
Incentive pool, withhold adjustments and bonus amounts	1,065,070
Subtotal	\$ 675,903,288
Less:	
Net reinsurance recoveries	46,403,598
Total hospital and medical	\$ 629,499,690
Claims adjustment expenses, including cost containment expenses	18,638,312
General administrative expenses	82,963,411
Increase in reserves for life and accident and health contracts	1,306,212
Total underwriting deductions	\$ 732,407,625
Net underwriting gain or (loss)	25,629,928
Net investment income earned	16,875,822
Net realized capital gains or (losses) less capital gains tax	2,646,397
Net investment gains or (losses)	\$ 19,522,219
Aggregate write-ins for other income or expenses	(9,423,552)
Net income or (loss) after capital gains tax and before all other federal income	
taxes	\$ 35,728,595
Federal and foreign income taxes incurred	4,883,442
Net income (loss)	\$ 30,845,153

Reconciliation of Capital and Surplus
For the Period from the Prior Examination
As of December 31, 2019, to December 31, 2021

December 31, 2019	Aggregate Write- ins for Special Surpus Funds \$ 14,204,788	\$ Unassigned Surplus 396,176,677	\$ Capital and Surplus 410,381,465
Operations 2020 $^{(1)}$	-	28,969,795	28,969,795
Operations 2021 (2)	-	37,404,782	37,404,782
December 31, 2021 (3)	\$ -	\$ 462,551,254	\$ 462,551,254
(1) Represents: Net income Change in unrealized capital gain Change in unrealized foreign exc Change in net deferred income ta Change in non-admitted assets Net Change in Surplus	change gain(losses)	\$ 29,528,776 (4,879,826) 6,795,440 (2,474,595) 28,969,795	
(2) Represents: Net income Change in unrealized capital gain Change in unrealized foreign exc Change in net deferred income ta Change in non-admitted assets Aggregate write-ins for gains or Net Change in Surplus	change gain(losses) ax	\$ 30,845,153 9,763,878 (1,955,010) 1,471,437 (16,925,464) 23,199,994	

(3) The Corporation was subject to an annual fee under Section 9010 of the ACA. This annual fee was allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that was written during the preceding calendar year. As of December 31, 2019, the estimated fee of \$14,204,788 for 2020 was reclassed from unassigned funds (surplus) to aggregate write-ins for special surplus funds in accordance with applicable statutory guidance. The annual fee has been repealed beginning in 2021, and therefore the Corporation did not reflect an amount in aggregate write-ins for special surplus funds at December 31, 2020, but reclassified these funds back to unassigned funds (surplus). As of December 31, 2021, no amounts were presented as aggregate write-ins for special surplus funds.

ANALYSIS OF CHANGES IN FINANCIAL STATEMENTS RESULTING FROM THE EXAMINATION

There were no changes made to the financial statements as a result of this examination.

COMMENTS ON FINANCIAL STATEMENT ITEMS

Note 1: Claims unpaid

In order for the examination team to gain an adequate comfort level with the Company's reserve estimates, the Department retained the actuarial services of INS Consultants, Inc. (INS) to perform a risk-focused review of the Company's reserving and pricing activities. Certain risks within the pricing and reserving processes required Phase 5 substantive test work.

Based on the procedures performed and results obtained by INS, the examination team obtained sufficient evidence to support the conclusion that the Company's net reserve estimates were reasonably stated as of December 31, 2021.

SUBSEQUENT EVENTS

The following material subsequent events occurred, requiring disclosure in this examination report.

Risk Sharing Agreement

On May 14, 2021, the Company entered into a Medicare Advantage Risk Sharing Agreement (Agreement) with Leeward Health, LLC (Newco). Newco is a joint venture formed for the purpose of entering into and performing this Agreement, the sole members of which are Christiana Care Health System, Inc. (CCHS) and Bayhealth Medical Center, Inc. (BMC). CCHS and BMC are independent entities that provide health care services through their respective hospitals and other health facilities and programs in the State of Delaware.

The Company, CCHS and BMC believe that Delaware seniors do not currently have access to the full spectrum of Medicare insurance coverages, which limits their access to quality health care. In order to address this concern, the Parties collaborated in the development, implementation and operation of a new competitive Medicare Advantage product in the State of Delaware (the MA Product) with the goals of improving clinical outcomes for Delaware seniors, aligning the objectives of the Parties and eliminating redundancies and managing outcomes and costs in a way that produces a sustainable product. The Agreement defines the responsibilities of the parties, establishment of an MA Product Steering Committee, financial arrangements, intellectual property, term and termination, restrictive covenants, indemnification and dispute resolution as well as other key items pertinent to the establishment of the Agreement.

The initial term of the Agreement is for a five (5) year period commencing on the effective date and shall automatically renew for a successive two (2) year terms following the end of the initial term and each renewal term unless either Party provides the other Party with written notice of non-renewal not less than one hundred eighty (180) days prior to the expiration of the thencurrent Term.

SUMMARY OF RECOMMENDATIONS

There were no examination report findings or recommendations as a result of the December 31, 2021, examination.

The assistance and cooperation of the Company's outside audit firm, PwC, and the Company's management and staff was appreciated and is acknowledged.

Respectfully submitted,

Keith E. Misenheimer, CFE, ALMI, CFE, ARM Examiner-In-Charge State of Delaware

Tony Cardone, CPA, CFE Supervising Examiner State of Delaware

I, Keith E. Misenheimer, hereby verify and attest, under penalty of perjury, that the above is a true and correct copy of the examination report and findings submitted to the Delaware Department of Insurance pursuant to Examination Certification No. 22,013.

In Keith E. Misenheimer, CFE, ALMI, CFE, ARM